Deschloroclozapine exhibits an exquisite agonistic effect at lower concentration compared to clozapine-N-oxide in hM3Dq expressing chemogenetically modified rats

IntroductionWithin the realm of chemogenetics, a particular form of agonists targeting designer receptors exclusively activated by designer drugs (DREADDs) has emerged. Deschloroclozapine (DCZ), a recently introduced DREADDs agonist, demonstrates remarkable potency in activating targeted neurons at...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Makiko Shimizu, Mitsuhiro Yoshimura, Kazuhiko Baba, Naofumi Ikeda, Yuki Nonaka, Takashi Maruyama, Tatsushi Onaka, Yoichi Ueta
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-11-01
Saila:	Frontiers in Neuroscience
Gaiak:	deschloroclozapine clozapine-N-oxide DREADDs oxytocin central nervous system Fos
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fnins.2023.1301515/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!